Key Points Amgen maintains a massive, diversified portfolio of medicines serving approximately 17 million patients globally. Vertex Pharmaceuticals dominates the cystic fibrosis market with exceptionally high net margins and a pristine balance sheet. Which of these established leaders is the better addition to your portfolio today? 10 stocks we like better than Amgen › Choosing between Amgen (NASDAQ:AMGN) and Vertex Pharmaceuticals (NASDAQ:VRTX) requires balancing the stability of a diversified pharmaceutical giant against the high-growth, high-margin profile of a specialized biotechnology pioneer.
Главную мысль мы показываем публично. Создайте бесплатный аккаунт, чтобы читать статью полностью, сохранять ее, обсуждать и связывать с рынками и OSINT-контекстом.